There was an omission in the funding information. The correct funding information is as follows: "The study was sponsored by the National Research Foundation of Singapore (Experimental Therapeutics Program), the Pharmacogenomics of Anticancer Agents Research (PAAR) Group, NIH/NIGMS U01GM61393 and the National Medical Research Council of Singapore (NMRC/CSA/021/2010). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."
Citation: Wang L-Z, Ramírez J, Yeo W, Chan M-YM, Thuya W-L, Lau J-YA, et al. (2014) Correction: Glucuronidation by UGT1A1 Is the Dominant Pathway of the Metabolic Disposition of Belinostat in Liver Cancer Patients. PLoS ONE 9(1): 10.1371/annotation/df796504-a2ea-4807-a412-85985bb2550b. https://doi.org/10.1371/annotation/df796504-a2ea-4807-a412-85985bb2550b
Published: January 13, 2014
Copyright: © 2014 . This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Competing interests: No competing interests declared.